Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact

Leukemia. 2000 Jun;14(6):1154. doi: 10.1038/sj.leu.2401804.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acute Disease
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chromosome Inversion*
  • Chromosomes, Human, Pair 16*
  • Cytarabine / administration & dosage
  • DNA-Binding Proteins / genetics*
  • Etoposide / administration & dosage
  • Gene Deletion*
  • Humans
  • Idarubicin / administration & dosage
  • In Situ Hybridization, Fluorescence
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / genetics*
  • Mitoxantrone / administration & dosage
  • Multidrug Resistance-Associated Proteins*
  • MutS Homolog 3 Protein
  • Prognosis
  • Prospective Studies
  • Recurrence
  • Remission Induction

Substances

  • DNA-Binding Proteins
  • MSH3 protein, human
  • Multidrug Resistance-Associated Proteins
  • MutS Homolog 3 Protein
  • Cytarabine
  • Etoposide
  • Mitoxantrone
  • multidrug resistance-associated protein 1
  • Idarubicin

Supplementary concepts

  • ICE protocol 4
  • NOAC protocol